AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37565934 — intervention group
Group type: EXPERIMENTAL
Intervention: No intervention
Number of subjects: 42489
Study 37565964 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stent strategy
Number of subjects: 345
Study 37565964 — intervention group
Group type: COMPARATOR
Intervention: 2-stent strategy
Number of subjects: 345
Study 37565973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050
Study 37565977 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest IL-6 levels
Number of subjects: 374
Study 37566218 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 11231
Study 37566253 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based multidisciplinary group intervention program (10-week duration, including twice-weekly exercise sessions and weekly education sessions)
Number of subjects: 60
Study 37566253 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based multidisciplinary group intervention program
Number of subjects: 60
Study 37566253 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 37566295 — intervention group
Group type: EXPERIMENTAL
Intervention: 2MACE score
Number of subjects: 25696
Study 37566431 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced mailed FIT outreach (tailored advance notification via text message or live phone call, plus two automated phone call reminders)
Number of subjects: 27585
Study 37566431 — intervention group
Group type: COMPARATOR
Intervention: Standard mailed FIT outreach (mailed FIT and live telephone reminders)
Number of subjects: 27585
Study 37566431 — intervention group
Group type: COMPARATOR
Intervention: Standard mailed FIT outreach
Number of subjects: 27585
Study 37566431 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced program (text message plus automated call reminder)
Number of subjects: 27585
Study 37566431 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced program (live phone calls plus automated call reminder)
Number of subjects: 27585
Study 37566449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB) intervention
Number of subjects: 210
Study 37566449 — intervention group
Group type: COMPARATOR
Intervention: Usual prenatal care
Number of subjects: 210
Study 37566578 — intervention group
Group type: EXPERIMENTAL
Intervention: OT infusion at 3.3 mU/min in women with morbid obesity
Number of subjects: 40
Study 37566578 — intervention group
Group type: COMPARATOR
Intervention: OT infusion in women with non-obesity and obesity
Number of subjects: 40
Study 37566578 — intervention group
Group type: EXPERIMENTAL
Intervention: OT infusion in women with obesity
Number of subjects: 40
Study 37566578 — intervention group
Group type: EXPERIMENTAL
Intervention: OT infusion in women with morbid obesity
Number of subjects: 40
Study 37566892 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 0
Study 37566892 — intervention group
Group type: COMPARATOR
Intervention: Control group (not infected with SARS-CoV-2)
Number of subjects: 0
Study 37567022 — intervention group
Group type: EXPERIMENTAL
Intervention: Premounted dry-pericardium Vienna Self-Expandable Aortic Valve System
Number of subjects: 10
Study 37567038 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous self-regulation
Number of subjects: 236
Study 37567038 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-persons model
Number of subjects: 236
Study 37567038 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-persons model
Number of subjects: 236
Study 37567205 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir (600 mg) plus rilpivirine (900 mg) dosed intramuscularly every 2 months
Number of subjects: 687
Study 37567205 — intervention group
Group type: COMPARATOR
Intervention: Bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) taken daily
Number of subjects: 687
Study 37567363 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Number of subjects: 37
Study 37567363 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous TBS (cTBS)
Number of subjects: 37
Study 37567363 — intervention group
Group type: COMPARATOR
Intervention: baseline nonstimulation control session
Number of subjects: 37
Study 37567391 — intervention group
Group type: EXPERIMENTAL
Intervention: PM-RUF
Number of subjects: 871
Study 37567391 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-RUF
Number of subjects: 871
Study 37567391 — intervention group
Group type: COMPARATOR
Intervention: FP
Number of subjects: 871
Study 37567614 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth differentiation factor (GDF)-15 measurement
Number of subjects: 2166
Study 37567614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards modelling, Net Reclassification Improvement, decision curve analysis
Number of subjects: 2166
Study 37567748 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT) group: 30 min of gait training using an exoskeleton (ANGEL LEGS M20, Angel Robotics) and 30 min of conventional gait training, total of 20 sessions (60 min/session); 5 sessions a week for 4 weeks.
Number of subjects: 150
Study 37567748 — intervention group
Group type: COMPARATOR
Intervention: Control group: 60 min of conventional gait training, total of 20 sessions (60 min/session); 5 sessions a week for 4 weeks.
Number of subjects: 150
Study 37567750 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg two times a day
Number of subjects: 5022
Study 37567750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5022
Study 37567779 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor IX Fc fusion protein (rFIX-Fc)
Number of subjects: 37
Study 37567779 — intervention group
Group type: COMPARATOR
Intervention: Published population PK model
Number of subjects: 37
Study 37567793 — intervention group
Group type: EXPERIMENTAL
Intervention: CIBM model
Number of subjects: 1380
Study 37567793 — intervention group
Group type: EXPERIMENTAL
Intervention: PulmoSeek Plus model
Number of subjects: 1380
Study 37568076 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Level ESPB (n=30) with 30 ml 0.25% bupivacaine
Number of subjects: 60
Study 37568076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-Level ESPB (n=30) with 15 ml 0.25% bupivacaine at T4 and T6 levels
Number of subjects: 60
Study 37568081 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (ESK) + standard of care (SOC)
Number of subjects: 451
Study 37568081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + standard of care (SOC)
Number of subjects: 451
Study 37568128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 4 - healthiest lifestyle pattern (n=302)
Number of subjects: 1183
Study 37568128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3 - active and shorter sleepers (n=280)
Number of subjects: 1183
Study 37568128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 - lower activity and longer sleepers (n=388)
Number of subjects: 1183
Study 37568128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 - higher screen time and poorer diet (n=213)
Number of subjects: 1183
Study 37568154 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceneuramic acid (SA-ER)
Number of subjects: 14
Study 37568154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 37568158 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (20 g thrice a day for 4 weeks)
Number of subjects: 174
Study 37568158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 4 weeks)
Number of subjects: 174
Study 37568172 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated health information technology (HIT) and peer-based support strategy
Number of subjects: 0
Study 37568172 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer component of the intervention
Number of subjects: 0
Study 37568172 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT component of the intervention
Number of subjects: 0
Study 37568172 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement strategies
Number of subjects: 0
Study 37568171 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-based interventions for GDM detection and management
Number of subjects: 60
Study 37568206 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical assistance and support from implementation support practitioners (ISPs)
Number of subjects: 150
Study 37568206 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual learning sessions
Number of subjects: 150
Study 37568206 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person support from ISPs
Number of subjects: 150
Study 37568206 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote support
Number of subjects: 150
Study 37568206 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual formats of training and technical assistance
Number of subjects: 150
Study 37568212 — intervention group
Group type: EXPERIMENTAL
Intervention: Structure Learning training (at least 13 sessions over 2 weeks)
Number of subjects: 0
Study 37568212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training, never exposed to Structure Learning task)
Number of subjects: 0
Study 37568216 — intervention group
Group type: EXPERIMENTAL
Intervention: C.S.I. training
Number of subjects: 30
Study 37568216 — intervention group
Group type: COMPARATOR
Intervention: Traditional vestibular rehabilitation
Number of subjects: 30
Study 37568242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 250
Study 37568242 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam
Number of subjects: 250
Study 37568381 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate 2 hours before elective cesarean delivery
Number of subjects: 148
Study 37568381 — intervention group
Group type: COMPARATOR
Intervention: Standard fasting
Number of subjects: 148
Study 37568391 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation (PTNS) with duloxetine (30 mg/day)
Number of subjects: 64
Study 37568391 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (30 mg/day) only
Number of subjects: 64
Study 37568402 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Number of subjects: 0
Study 37568622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 21 days
Number of subjects: 5
Study 37568887 — intervention group
Group type: EXPERIMENTAL
Intervention: New urinary biomarkers for renal injury diagnosis in patients treated with ICIs
Number of subjects: 0
Study 37568887 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic methods for renal injury
Number of subjects: 0
Study 37568975 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiology-guided incremental optimisation strategy (PIOS)
Number of subjects: 114
Study 37568975 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI FFR <0.90
Number of subjects: 114
Study 37569880 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 37569880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 37570430 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational solutions (360 V, VR, web-based information, psychoeducation)
Number of subjects: 350
Study 37570430 — intervention group
Group type: COMPARATOR
Intervention: Natural intervention (absence of intervention)
Number of subjects: 350
Study 37572086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib maintenance (560 mg/d)
Number of subjects: 20
Study 37572581 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally produced fish-based ready-to-use therapeutic food (L-RUTF)
Number of subjects: 121
Study 37572581 — intervention group
Group type: COMPARATOR
Intervention: Standard milk-based ready-to-use therapeutic food (S-RUTF)
Number of subjects: 121
Study 37572581 — intervention group
Group type: EXPERIMENTAL
Intervention: Both L-RUTF and S-RUTF
Number of subjects: 121
Study 37572618 — intervention group
Group type: EXPERIMENTAL
Intervention: PNE + exercise
Number of subjects: 30
Study 37572618 — intervention group
Group type: COMPARATOR
Intervention: exercise alone
Number of subjects: 30
Study 37572646 — intervention group
Group type: COMPARATOR
Intervention: Serpin family C member 1 (SERPINC1)
Number of subjects: 0
Study 37572646 — intervention group
Group type: COMPARATOR
Intervention: Fetuin B (FETUB)
Number of subjects: 0
Study 37572659 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63-MVA RH5 vaccine
Number of subjects: 0
Study 37572785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cre8 amphilimus-eluting stent
Number of subjects: 2107
Study 37572785 — intervention group
Group type: COMPARATOR
Intervention: SYNERGY everolimus-eluting stent
Number of subjects: 2107
Study 37572785 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized duration of DAPT (based on DAPT score)
Number of subjects: 2107
Study 37572785 — intervention group
Group type: COMPARATOR
Intervention: Standard duration of DAPT (12 months)
Number of subjects: 2107
Study 37572891 — intervention group
Group type: EXPERIMENTAL
Intervention: VBX stent
Number of subjects: 73
Study 37573155 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mA electrical stimulus
Number of subjects: 31
Study 37573155 — intervention group
Group type: COMPARATOR
Intervention: Behavioural Pain Scale
Number of subjects: 31
Study 37573292 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% cymenol mouthwash for eight days (test group A)
Number of subjects: 50
Study 37573292 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash for four days followed by 0.1% cymenol mouthwash for four days (test group B)
Number of subjects: 50
Study 37573322 — intervention group
Group type: EXPERIMENTAL
Intervention: CR500® treatment applied topically twice a week for 4 weeks
Number of subjects: 35
Study 37573322 — intervention group
Group type: EXPERIMENTAL
Intervention: CR500® treatment
Number of subjects: 35
Study 37573339 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based assessment of features derived from clinical, neurologic, and neuropsychological examinations, cognitive reserve estimation, depression evaluation, personality traits assessment, APOE and BDNF genotyping, electroencephalography, event-related potential recording, and lumbar puncture for Aβ measurement.
Number of subjects: 0
Study 37573339 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning application to predict Alzheimer's Disease in patients with SCD.
Number of subjects: 0
Study 37573366 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated GFAp at follow-up 3-6 months after ICU discharge
Number of subjects: 57
Study 37573366 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAp levels in patients experiencing different dimensions of fatigue
Number of subjects: 57
Study 37573366 — intervention group
Group type: EXPERIMENTAL
Intervention: NfL concentration at follow-up
Number of subjects: 57
Study 37573421 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly multi-disciplinary team-based case consultation and peer-to-peer sharing of emerging best practices (teleECHO) with monthly interactive webinars and quarterly short courses
Number of subjects: 856
Study 37573421 — intervention group
Group type: COMPARATOR
Intervention: Monthly interactive webinars and quarterly short courses
Number of subjects: 856
Study 37573428 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component behavior change technique (BCT) intervention
Number of subjects: 42
Study 37573534 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) plus lurasidone (NRX-101)
Number of subjects: 22
Study 37573534 — intervention group
Group type: COMPARATOR
Intervention: lurasidone alone
Number of subjects: 22
Study 37573936 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (62.1% of patients, mean duration 34.9 ± 15.7 days)
Number of subjects: 872
Study 37573936 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) (25.0% of patients, mean duration 26.2 ± 23.2 days)
Number of subjects: 872
Study 37573936 — intervention group
Group type: EXPERIMENTAL
Intervention: Any other anticoagulants (6.2%)
Number of subjects: 872
Study 37573936 — intervention group
Group type: EXPERIMENTAL
Intervention: No anticoagulant (6.7%)
Number of subjects: 872
Study 37573936 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 872
Study 37573968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 2180
Study 37573968 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2180
Study 37573968 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-guided discontinuation
Number of subjects: 2180
Study 37573968 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruption of DAPT
Number of subjects: 2180
Study 37574002 — intervention group
Group type: EXPERIMENTAL
Intervention: ECPR
Number of subjects: 174
Study 37574002 — intervention group
Group type: COMPARATOR
Intervention: ROSC
Number of subjects: 174
Study 37574027 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine
Number of subjects: 1683
Study 37574027 — intervention group
Group type: EXPERIMENTAL
Intervention: Other measured metabolites (except γ-butyrobetaine and carnitine)
Number of subjects: 1683
Study 37574132 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (7-d lead-in, 90 mg)
Number of subjects: 248
Study 37574132 — intervention group
Group type: COMPARATOR
Intervention: Alectinib 600 mg twice daily
Number of subjects: 248
Study 37574132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (exploratory analysis)
Number of subjects: 248
Study 37574132 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 248
Study 37574132 — intervention group
Group type: COMPARATOR
Intervention: Alectinib
Number of subjects: 248
Study 37574143 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic group (41 men)
Number of subjects: 116
Study 37574143 — intervention group
Group type: COMPARATOR
Intervention: Antithrombotic-naïve group (75 men)
Number of subjects: 116
Study 37574209 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 376
Study 37574209 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 376
Study 37574209 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptional DDR markers
Number of subjects: 376
Study 37574463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar-I
Number of subjects: 362
Study 37574463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar-II
Number of subjects: 362
Study 37574463 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD
Number of subjects: 362
Study 37574463 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 362
Study 37574511 — intervention group
Group type: EXPERIMENTAL
Intervention: Envonalkib
Number of subjects: 264
Study 37574511 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 264
Study 37574558 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational use of NIV masks every 6 hours.
Number of subjects: 239
Study 37574558 — intervention group
Group type: COMPARATOR
Intervention: Standard of care NIV mask selection and change based on discomfort or new pressure sores.
Number of subjects: 239
Study 37574601 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to childhood PTEs, particularly direct interpersonal violence
Number of subjects: 2947
Study 37574601 — intervention group
Group type: COMPARATOR
Intervention: Psychological symptoms and pain
Number of subjects: 2947
Study 37574610 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM5 (5 mg)
Number of subjects: 321
Study 37574610 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM10 (10 mg)
Number of subjects: 321
Study 37574610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 37574610 — intervention group
Group type: COMPARATOR
Intervention: Placebo non-responders
Number of subjects: 321
Study 37574661 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 22
Study 37574780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad-HSV1-TK/GCV and Ad-Flt3L gene therapy
Number of subjects: 0
Study 37574821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem infusions of MIITOP
Number of subjects: 30
Study 37574821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem infusions of MIITOP followed by busulfan-melphalan
Number of subjects: 30
Study 37574953 — intervention group
Group type: EXPERIMENTAL
Intervention: lanadelumab 300 mg every 2 weeks subcutaneously for 52 weeks (with possible reduction to 300 mg every 4 weeks during the second 26-week period if well-controlled)
Number of subjects: 12
Study 37574953 — intervention group
Group type: EXPERIMENTAL
Intervention: lanadelumab 300 mg every 2 weeks subcutaneously for 52 weeks
Number of subjects: 12
Study 37574953 — intervention group
Group type: EXPERIMENTAL
Intervention: lanadelumab
Number of subjects: 12
Study 37574994 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Partner intervention
Number of subjects: 3
Study 37574994 — intervention group
Group type: COMPARATOR
Intervention: Ordinary child welfare services
Number of subjects: 3
Study 37575149 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient+ used at least once daily
Number of subjects: 56
Study 37575193 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-surgical methemoglobin levels
Number of subjects: 0
Study 37575193 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative hemoglobin concentration (Hb)
Number of subjects: 0
Study 37575193 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint (death, myocardial infarction, stroke, severe acute kidney injury at 28 days)
Number of subjects: 0
Study 37575226 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with live bacteria (specific details not provided in the abstract)
Number of subjects: 0
Study 37575226 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not provided in the abstract)
Number of subjects: 0
Study 37575326 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic ketogenic diet
Number of subjects: 6
Study 37575420 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-guided meditation intervention (8 sessions of 15-min each, twice weekly for 4 weeks)
Number of subjects: 30
Study 37575420 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-guided meditation intervention
Number of subjects: 30